Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...

Bain Capital, an investment firm that has spread ... and diabetes and metabolic disease. The unit’s top-selling product is the amyotrophic lateral sclerosis drug Radicava, which accounted ...

Brentwood, Tenn.-based Surgery Partners received a nonbinding acquisition proposal from Bain Capital Private Equity on Jan. 27, offering to buy all outstanding shares for $25.75 per share in cash.

Bain Capital Private Equity has proposed to acquire the remaining shares of surgical facility operator Surgery Partners it ...

Bain Capital is in talks to acquire Mitsubishi Chemical Group’s41880.31%increase; green up pointing triangle pharmaceutical business in a potential multibillion-dollar deal, a person familiar ...

The provider of highly-engineered processing equipment and solutions will sell a 51% stake in the injection molding and extrusion business for $287 million.

Tokyo, Feb. 7 (Jiji Press)--Mitsubishi Chemical Group Corp. said Friday that it will sell subsidiary Mitsubishi Tanabe Pharma Corp. to U.S. investment firm Bain Capital LP. for about 510 billion yen.

The American investment company Bain Capital is considering the sale of Italmatch Chemicals SpA, an Italian manufacturer of specialty chemicals. This is reported in a press release from Bain Capital.

the company entered into a definitive agreement to sell an ownership stake of approximately 51% in its Milacron injection molding and extrusion business to an affiliate of Bain Capital for $287M ...

TOKYO (Reuters) - Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3. ...